Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Wilko Weichert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6139-8372; OpenAlex author ID A5018744564, A5031018397, A5060327821. Sources: OpenAlex.

Their work

Papers
45 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
166
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 6 papers · 2019: 4 papers · 2020: 7 papers · 2021: 7 papers · 2022: 7 papers · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 45

  1. Correction to: Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induce… Co-author DOI 10.1007/s00259-025-07195-1↗
  2. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  3. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  4. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  5. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin. Co-author DOI 10.1007/s00259-021-05559-x↗
  6. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascular… Co-author DOI 10.1007/s00259-022-05930-6↗
  7. The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping. Co-author DOI 10.1093/narcan/zcac030↗
  8. Transcriptionally defined morphological subtypes of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2022.09.23.509133↗
  9. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  10. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  11. MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases. Co-author DOI 10.3390/molecules27154811↗
  12. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
  13. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. Co-author DOI 10.1172/jci.insight.141532↗
  14. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00808-4↗
  15. Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00862-y↗
  16. Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Co-author DOI 10.3390/cancers13092069↗
  17. Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13163969↗
  18. Histopathological Tumor and Normal Tissue Responses after 3D-Planned Arc Radiotherapy in an Orthotopic Xenograft Mouse Model of Human Pancreatic Cancer. Co-author DOI 10.3390/cancers13225656↗
  19. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  20. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Co-author DOI 10.1158/1078-0432.ccr-19-1864↗
  21. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  22. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Co-author DOI 10.1172/jci136760↗
  23. New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.14292↗
  24. Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9030724↗
  25. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Co-author DOI 10.3390/jcm9051250↗
  26. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Co-author DOI 10.1186/s41747-019-0119-0↗
  27. Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological … Co-author DOI 10.1371/journal.pone.0208717↗
  28. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX … Co-author DOI 10.1371/journal.pone.0218642↗
  29. Still a hopeless case for personalized oncology? Pancreatic cancer revisited. Co-author DOI 10.18632/oncoscience.464↗
  30. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  31. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  32. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  33. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002345↗
  34. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Last author DOI 10.1158/1078-0432.ccr-17-2180↗
  35. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0036↗
  36. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejca.2017.06.034↗
  37. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrosp… Co-author DOI 10.1016/j.pan.2017.04.012↗
  38. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. Co-author DOI 10.15252/emmm.201607354↗
  39. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  40. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2014.217↗
  41. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicat… Co-author DOI 10.1097/mpa.0000000000000248↗
  42. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  43. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/1471-2407-13-450↗
  44. Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer. Co-author DOI 10.1007/s00595-011-0045-0↗
  45. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Co-author DOI 10.1111/j.1365-2559.2012.04225.x↗

Closest collaborators

The 25 strongest of 166 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rickmer Braren · 13 shared papers, 2019–2025 · strength 1.37
  2. Roland Michael Schmid · 12 shared papers, 2018–2025 · strength 1.16
  3. Jens Thomas Siveke · 10 shared papers, 2019–2025 · strength 1.14
  4. Georgios A. Kaissis · 10 shared papers, 2019–2025 · strength 1.05
  5. Alexander Muckenhuber · 14 shared papers, 2013–2021 · strength 1.05
  6. Fabian Karl Lohöfer · 9 shared papers, 2019–2025 · strength 0.98
  7. Maximilian Reichert · 9 shared papers, 2018–2025 · strength 0.89
  8. Anna Melissa Schlitter · 9 shared papers, 2017–2023 · strength 0.89
  9. Felix N. Harder · 7 shared papers, 2020–2025 · strength 0.83
  10. Helmut Friess · 8 shared papers, 2017–2022 · strength 0.72
  11. İhsan Ekin Demir · 6 shared papers, 2017–2025 · strength 0.67
  12. Sebastian Ziegelmayer · 7 shared papers, 2019–2021 · strength 0.66
  13. Hana Algül · 6 shared papers, 2019–2025 · strength 0.66
  14. Marija Trajkovic‐Arsic · 4 shared papers, 2021–2025 · strength 0.54
  15. Helmut Frieß · 6 shared papers, 2018–2021 · strength 0.53
  16. Günter Schneider · 7 shared papers, 2018–2022 · strength 0.53
  17. Dieter Saur · 7 shared papers, 2018–2022 · strength 0.53
  18. Guralp Onur Ceyhan · 7 shared papers, 2017–2020 · strength 0.53
  19. H. Carlo Maurer · 4 shared papers, 2021–2025 · strength 0.52
  20. Irina Heid · 4 shared papers, 2020–2025 · strength 0.49
  21. Lucia Liotta · 4 shared papers, 2020–2025 · strength 0.49
  22. Roland Rad · 6 shared papers, 2018–2022 · strength 0.47
  23. Felix Orben · 4 shared papers, 2020–2025 · strength 0.47
  24. Friederike Jungmann · 4 shared papers, 2020–2021 · strength 0.41
  25. Martin Ronald Sprick · 5 shared papers, 2015–2019 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.